Abdullah Cetin Tanrikulu1, Abdurrahman Abakay2, Halil Komek3, Ozlem Abakay1. 1. Department of Chest Diseases, Medical School of Dicle University, Diyarbakir, Turkey. 2. Department of Chest Diseases, Medical School of Dicle University, Diyarbakir, Turkey. arahmanabakay@hotmail.com. 3. Department of Nuclear Medicine, Diyarbakir Education and Training Hospital, Diyarbakir, Turkey.
Abstract
OBJECTIVES: Inflammation plays a role in malignant pleural mesothelioma (MPM) prognosis and symptoms. We investigated the roles of the new and old inflammatory indexes and markers in MPM prognosis. METHODS: Two hundred and ninety-two MPM patients (167 male and 125 female) were included in this retrospective study. Demographic parameters were collected from the patients' files. Kaplan-Meier curves and multivariate Cox regression analyses were used for the analysis of prognosis. RESULTS: The mean age of the patients was 58.4 years. The mean survival time was 14.6 ± 13.0 months. Twenty-four potential prognostic factors associated with a poor outcome were calculated in the univariate analysis, and 16 potential prognostic factors were associated with a poor prognosis. These 16 potential prognostic factors were also analyzed in multivariate analysis. Multivariate analysis showed that increased age, stage 3-4 disease, the non-epithelial type, a low Karnofsky performance score, a high white blood cell count, and a low lymphocyte-to-monocyte ratio (LMR) were associated with a poor prognosis. The results of the multivariate analysis showed that a decreased LMR was associated with poor survival. Patients with LMR ≤2.6 had poor survival compared with those with LMR >2.6 (mean 9.6 vs. 17.0 months, respectively; p = 0.004). CONCLUSIONS: LMR is an independent marker of prognosis in patients with MPM and is superior to the other inflammation-based markers. The inexpensive nature and easy reproducibility of the hemogram should encourage the use of the LMR in clinical practice.
OBJECTIVES: Inflammation plays a role in malignant pleural mesothelioma (MPM) prognosis and symptoms. We investigated the roles of the new and old inflammatory indexes and markers in MPM prognosis. METHODS: Two hundred and ninety-two MPM patients (167 male and 125 female) were included in this retrospective study. Demographic parameters were collected from the patients' files. Kaplan-Meier curves and multivariate Cox regression analyses were used for the analysis of prognosis. RESULTS: The mean age of the patients was 58.4 years. The mean survival time was 14.6 ± 13.0 months. Twenty-four potential prognostic factors associated with a poor outcome were calculated in the univariate analysis, and 16 potential prognostic factors were associated with a poor prognosis. These 16 potential prognostic factors were also analyzed in multivariate analysis. Multivariate analysis showed that increased age, stage 3-4 disease, the non-epithelial type, a low Karnofsky performance score, a high white blood cell count, and a low lymphocyte-to-monocyte ratio (LMR) were associated with a poor prognosis. The results of the multivariate analysis showed that a decreased LMR was associated with poor survival. Patients with LMR ≤2.6 had poor survival compared with those with LMR >2.6 (mean 9.6 vs. 17.0 months, respectively; p = 0.004). CONCLUSIONS:LMR is an independent marker of prognosis in patients with MPM and is superior to the other inflammation-based markers. The inexpensive nature and easy reproducibility of the hemogram should encourage the use of the LMR in clinical practice.
Authors: Steven Chuan-Hao Kao; Sonja Klebe; Douglas W Henderson; Glen Reid; Mark Chatfield; Nicola J Armstrong; Tristan D Yan; Janette Vardy; Stephen Clarke; Nico van Zandwijk; Brian McCaughan Journal: J Thorac Oncol Date: 2011-11 Impact factor: 15.609
Authors: Steven C H Kao; Nick Pavlakis; Rozelle Harvie; Janette L Vardy; Michael J Boyer; Nico van Zandwijk; Stephen J Clarke Journal: Clin Cancer Res Date: 2010-10-18 Impact factor: 12.531
Authors: Jedd M Hillegass; Arti Shukla; Sherrill A Lathrop; Maximilian B MacPherson; Stacie L Beuschel; Kelly J Butnor; Joseph R Testa; Harvey I Pass; Michele Carbone; Chad Steele; Brooke T Mossman Journal: Ann N Y Acad Sci Date: 2010-08 Impact factor: 5.691
Authors: Jason F Lester; Angela C Casbard; Saly Al-Taei; Richard Harrop; Lajos Katona; Richard L Attanoos; Zsuzsanna Tabi; Gareth O Griffiths Journal: Oncoimmunology Date: 2018-09-07 Impact factor: 8.110
Authors: Shu Wen; Nan Chen; Ying Hu; Litao Huang; Jin Peng; Meina Yang; Xiaoyang Shen; Yang Song; Liangzhi Xu Journal: Cancer Med Date: 2021-02-16 Impact factor: 4.452